Sanofi/Genzyme MS Drug Lemtrada Scores High Against Rebif
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genzyme, a Sanofi company, set the bar high for its multiple sclerosis contender by stacking it up against Roche’s interferon beta-1a in Phase III trials and got the results it was looking for, with a filing set for this quarter.